{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:29:56Z","timestamp":1784204996821,"version":"3.55.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Idiopathic multicentric Castleman disease (iMCD) is a rare, life-threatening subtype of Castleman disease (CD), which describes a group of rare, polyclonal lymphoproliferative disorders that demonstrate characteristic histopathology and variable symptomatology. iMCD involves a cytokine storm that occurs due to an unknown cause. Rapid diagnosis is required to initiate appropriate, potentially life-saving therapy, but diagnosis is challenging and impeded by clinical overlap with a wide spectrum of inflammatory, neoplastic, and infectious causes of generalized lymphadenopathy. Diagnosis, which requires both consistent histopathologic and clinical criteria, can be further delayed in the absence of close collaboration between clinicians and pathologists. A multimodal assessment is necessary to effectively discriminate iMCD from overlapping diseases. In this review, we discuss a pragmatic approach to generalized lymphadenopathy and clinical, laboratory, and histopathological features that can aid with identifying iMCD. We discuss diagnostic barriers that impede appropriate recognition of disease features, diagnostic criteria, and evidence-based treatment recommendations that should be initiated immediately following diagnosis.<\/jats:p>","DOI":"10.1182\/hematology.2024000582","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:05:32Z","timestamp":1733497532000},"page":"582-593","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy"],"prefix":"10.1182","volume":"2024","author":[{"given":"Sally","family":"Nijim","sequence":"first","affiliation":[{"name":"Raymond and Ruth Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Fajgenbaum","sequence":"additional","affiliation":[{"name":"Raymond and Ruth Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"16","key":"2024121115465159100_hem2024000582C1","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood.2019000931","article-title":"Overview of Castleman disease","volume":"135","author":"Dispenzieri","year":"2020","journal-title":"Blood"},{"issue":"22","key":"2024121115465159100_hem2024000582C2","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2018-05-848671","article-title":"Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease","volume":"132","author":"Fajgenbaum","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2024121115465159100_hem2024000582C3","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2024121115465159100_hem2024000582C4","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/rheumatology\/kead644","article-title":"Lymphadenopathy in the rheumatology practice: a pragmatic approach","volume":"63","author":"Rodolfi","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"2024121115465159100_hem2024000582C5","first-page":"e15925","article-title":"Coinfection of tuberculosis in an undiagnosed HIV, AIDS patient presenting with shortness of breath, constitutional symptoms and lymphadenopathy","volume":"13","author":"Garcia Rivera","year":"2021","journal-title":"Cureus"},{"issue":"10","key":"2024121115465159100_hem2024000582C6","first-page":"e30089","article-title":"Generalized lymphadenopathy as the first manifestation of systemic lupus erythematosus","volume":"14","author":"Soares","year":"2022","journal-title":"Cureus"},{"issue":"5","key":"2024121115465159100_hem2024000582C7","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jaip.2024.03.006","article-title":"Drugs associated with serum sickness and serum sickness-like reactions: a review of FDA Adverse Event Reporting System (FAERS) data","volume":"12","author":"Surdacki","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"2024121115465159100_hem2024000582C8","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1634\/theoncologist.2011-0075","article-title":"Castleman's disease: systematic analysis of 416 patients from the literature","volume":"16","author":"Talat","year":"2011","journal-title":"Oncologist"},{"issue":"4","key":"2024121115465159100_hem2024000582C9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/j.semdp.2012.07.001","article-title":"Lymphadenopathy of IgG4-related disease: an underdiagnosed and overdiagnosed entity","volume":"29","author":"Cheuk","year":"2012","journal-title":"Semin Diagn Pathol"},{"issue":"19","key":"2024121115465159100_hem2024000582C10","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1158\/1078-0432.CCR-15-0134","article-title":"Analysis of inflammatory and anemia- related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (anti-IL6 monoclonal antibody) in patients with multicentric Castleman disease","volume":"21","author":"Casper","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2024121115465159100_hem2024000582C11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejim.2016.08.026","article-title":"C-reactive protein (CRP) measurement in geriatric patients hospitalized for acute infection","volume":"37","author":"Ticinesi","year":"2017","journal-title":"Eur J Intern Med"},{"issue":"9","key":"2024121115465159100_hem2024000582C12","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1515\/cclm-2023-0086","article-title":"Why C-reactive protein is one of the most requested tests in clinical laboratories?","volume":"61","author":"Plebani","year":"2023","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"2024121115465159100_hem2024000582C13","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.7150\/thno.40606","article-title":"Differentiation of benign and malignant lymph nodes in pediatric patients on ferumoxytol-enhanced PET\/MRI","volume":"10","author":"Muehe","year":"2020","journal-title":"Theranostics"},{"issue":"2","key":"2024121115465159100_hem2024000582C14","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3324\/haematol.2019.219626","article-title":"Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease","volume":"105","author":"Goyal","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2024121115465159100_hem2024000582C15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41572-021-00307-9","article-title":"Histiocytic disorders","volume":"7","author":"McClain","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2024121115465159100_hem2024000582C16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s13139-017-0471-z","article-title":"Systemic lupus erythematosus associated pitfalls on 18F-FDG PET\/CT: reactive follicular hyperplasia, Kikuchi-Fujimoto disease, inflammation and lymphoid hyperplasia of the spleen mimicking lymphoma","volume":"52","author":"Makis","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"issue":"1","key":"2024121115465159100_hem2024000582C17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.hoc.2017.09.002","article-title":"Castleman disease pathogenesis","volume":"32","author":"Fajgenbaum","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"18","key":"2024121115465159100_hem2024000582C18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810301","article-title":"Idiopathic plasmacytic lymphadenopathy forms an independent subtype of idiopathic multicentric Castleman disease","volume":"23","author":"Nishikori","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2024121115465159100_hem2024000582C19","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1159\/000518079","article-title":"TAFRO syndrome and elusive diagnosis of idiopathic multicentric Castleman disease treated with empiric anti-interleukin-6 therapy","volume":"14","author":"Williams","year":"2021","journal-title":"Case Rep Oncol"},{"issue":"5","key":"2024121115465159100_hem2024000582C20","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/bjh.19334","article-title":"Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: a distinct subtype of iMCD-not otherwise specified with different clinical features and better survival","volume":"204","author":"Gao","year":"2024","journal-title":"Br J Haematol"},{"key":"2024121115465159100_hem2024000582C21","doi-asserted-by":"crossref","DOI":"10.1136\/jcp-2023-209280","article-title":"Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): factors to differentiate from IgG4-related disease","author":"Nishikori","year":"2024","journal-title":"J Clin Pathol"},{"issue":"2","key":"2024121115465159100_hem2024000582C22","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/bjh.15019","article-title":"The full spectrum of Castleman disease: 273 patients studied over 20 years","volume":"180","author":"Oksenhendler","year":"2018","journal-title":"Br J Haematol"},{"issue":"8","key":"2024121115465159100_hem2024000582C23","article-title":"Diagnostic value of lymph node fine-needle aspiration cytology","volume":"18","author":"Ton Eryilmaz","year":"2021","journal-title":"Cytojournal"},{"issue":"5","key":"2024121115465159100_hem2024000582C24","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/ejh.13578","article-title":"Lymph node core needle biopsy for the diagnosis of lymphoproliferative disorders: a word of caution","volume":"106","author":"Pizzi","year":"2021","journal-title":"Eur J Haematol"},{"issue":"10","key":"2024121115465159100_hem2024000582C25","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/ajh.26292","article-title":"Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease","volume":"96","author":"Nishimura","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"2024121115465159100_hem2024000582C26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/hematology.2023000509","article-title":"Inpatient recognition and management of HLH","volume":"2023","author":"Zoref-Lorenz","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"2024121115465159100_hem2024000582C27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.5858\/arpa.2018-0190-RS","article-title":"Autoimmune lymphoproliferative syndrome: an overview","volume":"144","author":"Matson","year":"2020","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"2024121115465159100_hem2024000582C28","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2214\/AJR.19.22334","article-title":"HIV lymphadenopathy: differential diagnosis and important imaging features","volume":"216","author":"Glushko","year":"2021","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"2024121115465159100_hem2024000582C29","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TNMI7-0013-2016","article-title":"Miliary tuberculosis","volume":"5","author":"Sharma","year":"2017","journal-title":"Microbiol Spectr"},{"issue":"3","key":"2024121115465159100_hem2024000582C30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2174\/1573396320666230801091558","article-title":"Infectious mononucleosis: an updated review","volume":"20","author":"Leung","year":"2024","journal-title":"Curr Pediatr Rev"},{"issue":"20","key":"2024121115465159100_hem2024000582C31","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"132","author":"van Rhee","year":"2018","journal-title":"Blood"},{"issue":"21","key":"2024121115465159100_hem2024000582C32","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1182\/bloodadvances.2023010745","article-title":"Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes","volume":"7","author":"Pierson","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"2024121115465159100_hem2024000582C33","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2016-11-748855","article-title":"Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease","volume":"129","author":"Yu","year":"2017","journal-title":"Blood"},{"issue":"16","key":"2024121115465159100_hem2024000582C34","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1182\/bloodadvances.2022007112","article-title":"Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease","volume":"6","author":"van Rhee","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"2024121115465159100_hem2024000582C35","first-page":"564","article-title":"How we manage idiopathic multicentric Castleman disease","volume":"20","author":"Brandstadter","year":"2022","journal-title":"Clin Adv Hematol Oncol"},{"issue":"16","key":"2024121115465159100_hem2024000582C36","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2018-11-884577","article-title":"Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease","volume":"133","author":"Zhang","year":"2019","journal-title":"Blood"},{"issue":"21","key":"2024121115465159100_hem2024000582C37","first-page":"2654","article-title":"A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in newly-diagnosed iMCD patients","volume":"141","author":"Zhao","year":"2023","journal-title":"Blood"},{"issue":"Suppl 1","key":"2024121115465159100_hem2024000582C38","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1182\/blood-2023-188076","article-title":"A translational approach to identifying and targeting TNF signaling in idiopathic multicentric Castleman disease","volume":"142","author":"Mumau","year":"2023","journal-title":"Blood"},{"issue":"17","key":"2024121115465159100_hem2024000582C39","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1182\/bloodadvances.2020004016","article-title":"Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease","volume":"5","author":"Pierson","year":"2021","journal-title":"Blood Adv"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/582\/2346815\/582nijim.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/582\/2346815\/582nijim.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T20:15:36Z","timestamp":1733948136000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/582\/526206\/Identifying-Castleman-disease-from-non-clonal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000582","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}